Mineralys Therapeutics (MLYS) Long-Term Investments (2023)
Quarterly results put Long-Term Investments at $2.5 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $2.5 million (changed N/A YoY), and the annual figure for FY2023 was $2.5 million, changed.
Mineralys Therapeutics has reported Long-Term Investments over the past 1 years, most recently at $2.5 million for Q4 2023.
- Long-Term Investments reached $2.5 million in Q4 2023 per MLYS's latest filing, down from $12.1 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $31.1 million in Q1 2023 and bottomed at $2.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 9.79 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 12.13 Mn |
| Jun 30, 2023 | 21.68 Mn |
| Mar 31, 2023 | 31.12 Mn |